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ABSTRACT 
Ischemic nephropathy is an emerging cause of end stage renal disease, associated with many co-morbidities es-
pecially cardiovascular disease risk and derangement in calcium-phosphorus homeostasis resulting in hyper-
phosphatemia, influencing bones, a characteristic of advancing chronic kidney disease. The management of ele-
vated serum phosphorus has been a challenge in this patient population with compromised kidney performance, 
as available phosphorus lowering agents possess many undesirable hazardous secondary effects and/or are very 
expensive. While niacin in different formulation is known to not only correct dyslipidemia but also reduce phos-
phorus level, but its clinical use restricted owing to side effects. The objective of present study is to evaluate 
such effect of niacin extended release (NER) in ischemic nephropathy. The chronic kidney disease patients ful-
filling the pre-defined criteria were randomly categorized into two groups of equal size (n=60) and prescribed 
either atorvastatin 20 mg/day or NER 500 mg/day with the same dose of statin for four months. A control of 50 
healthy characters matched was also incorporated for local reference range. Baseline and follow up phosphorus 
concentration was measured and means were compared using t-test at SPSS version 17 with 0.05 chosen alpha. 
There was no difference in the baseline levels in both groups while significant (p<0.001) hyperphosphatemia 
was observed in both units as compared with healthy controls. The administration of atorvastatin alone for four 
weeks showed an insignificant decrease in phosphorus, whereas, NER significantly reduced phosphorus 
(p<0.001). The mean percent change from baseline to follow up further endorsed the finding as statin alone 
brought -13.8 % reduction in phosphorus and NER -47 % from baseline. NER, at its lowest prescribed dose once 
a day was well tolerated by most of the patients and demonstrated significant goal achievement of phosphorus 
reduction. It is concluded that NER even at low doses in renal compromised dyslipidemic patients may be a 
promising approach to prevent the harmful vascular, valvular effects caused by hyperphosphatemia in addition to 
its principal target of HDL-C elevation. 
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INTRODUCTION 
Renal ischemia is an outcome of renal ar-
teriosclerosis manifested by kidney hypo-
perfusion beyond level of auto-regulation 
that brings significant decrease in glomerular 
filtration rate (GFR) by affecting the whole 
functional parenchyma following renal ves-
sel occlusion (Adamczak & Wiecek, 2012). 
The most prevailed etiological findings are 
hypertension, hypercholesterolemia and 
smoking (Yasmeen et al., 2014a; Alcazar et 
al., 2001).  
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In ischemic nephropathy where elevated 
cholesterol is one of the principal causes, the 
basic disease genesis mechanism is com-
prised of plaque formation in the renal artery 
producing an obstruction in the blood flow 
exposing the renal tissue to ischemia. The 
damage to functional parenchyma that im-
pairs the kidney physiology includes atro-
phied tubules, collapsed glomeruli and inter-
stitial fibrosis (Lerman and Textor, 2001).  
As kidneys are one of the vital organs re-
sponsible for the maintenance of homeosta-
sis by monitoring body fluid composition, 
their functional derangement is associated 
with many other clinically significant ab-
normalities like electrolyte imbalance, pH 
changes, ischemia, bone weakness etc. that 
may further favor disease development. In-
adequate homeostasis of calcium-phosphorus 
with markedly raised levels of phosphorus 
are supposed to participate actively in arteri-
al hardening, hypertension, and increased 
risk of vascular disease with advancing 
chronic renal disease (Levin et al., 2008; 
Melamed et al., 2006; Kestenbaum et al., 
2005; Menon et al., 2005). Researches based 
on population observational studies recom-
mended that though lying in the normal 
range, serum phosphorus levels are propor-
tional to initial events of arteriosclerosis 
genesis and the subsequent vascular out-
comes even when its subclinical (Onufrak et 
al., 2008, 2009; Foley et al., 2009; Ix et al., 
2009). The link between serum phosphorus 
levels and persistent atheriosclerotic meas-
ures in graded independent manner was rec-
orded in a clinical trial (Tonelli et al., 2005). 
Hyperphosphatemia has also been known 
responsible for lesser outcomes and in-
creased associated mortality in patients of 
compromised renal function. Therefore, in 
patients with chronic kidney disease, Kidney 
Disease Improving Global Outcomes (KDI-
GO) suggests reduction in enhanced concen-
trations of phosphorus toward normal range. 
The epidemiological studies are suggestive 
of the clinical basis to control serum phos-
phorus as they concluded up that hyperphos-
phatemia is a significant risk factor for sec-
ondary hyperparathyroidism and for cardio-
vascular disease (Block et al., 2004). Limited 
dietary phosphorus intake and clearance 
through dialysis are mostly insufficient to 
control serum phosphate. Therefore, there is 
need to start phosphate to lessen the dietary 
phosphorus absorbed through gut. The re-
cently used phosphate binders, though help-
ful, are not supposed suitable owing to their 
undesirable side effects including hyper-
calcemia, risk of potential toxicities (e.g., 
aluminum toxicity) and/or high cost (e.g. 
sevelamer and lanthanum carbonate) (Edalat-
Nejad et al., 2012).  
Calcium salts supplements, on the other 
side, are effective and well tolerable in con-
trolling phosphorus in end stage renal dis-
ease, but they favor cardiovascular disease 
and calcification of aortic valve (Block et al., 
2005). Summing up, a hyperphosphatemia 
treatment protocol is lacking with balanced 
efficacy and minimized secondary hazards 
(Coladonato, 2005; Qunibi et al., 2004). 
Phosphorus-reducing agents aimed to control 
CVD risk factors associated with CKD in-
cluding dyslipidemia also show preservative 
or synergistic advantage (Pennell et al., 
2006), that could also be applicable to indi-
viduals with early stages of CKD or having 
kidney functions in normal range.  
Niacin was first reported to decrease 
plasma cholesterol in 1955 (Altschul et al., 
1955). The major clinical application of nia-
cin has been to raise HDL and reduce tri-
glyceride levels.  
As niacin is converted largely to niacin-
amide, it also inhibits intestinal phosphate 
absorption. Early research experiments are 
suggestive that niacin intake might be bene-
ficial as prime or adjunctive therapy to treat 
pronounced hyperphosphatemia, a character-
istic feature of end stage renal disease 
(ESRD) (Sampathkumar, 2009; Sampathku-
mar et al., 2006; Cheng and Young, 2008). 
Substantial data from human trials regarding 
niacin extended-release (NER) administra-
tion in different patient populations demon-
strated 10 % drop in serum phosphorus from 
baseline values (Maccubbin et al., 2008; 
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Guyton et al., 2000). These frequent clinical 
trial findings can be justified from the direct 
inhibition of active transport-mediated phos-
phorus absorption induced by niacin in the 
gut. The reports of NER hypophosphatemic 
effects from patients with dyslipidemia 
lacked the information on baseline phospho-
rus values (Maccubbin et al., 2008; Guyton 
et al., 2000), therefore the present study was 
aimed to examine whether niacin extended 
release lowers serum levels of phosphorus 
when used in combination with classic 
treatment atorvastatin in patients with is-
chemic kidney disease.  
 
METHODOLOGY 
Study type  
It was hospital based, prospective, ran-
domized, analytical research plan that was 
executed in collaboration with Nephrology 
Unit of Jinnah Post Graduate Medical Cen-
tre, Karachi, Pakistan.  
 
Patient screening 
Initially information from all the patients 
visiting the Nephrology out patient depart-
ment treated for chronic kidney disease was 
collected. They were requested to answer a 
structured questionnaire inquiring about their 
medical history, current complaints, medica-
tion and known ischemic risk factors. The 
questionnaire was filled in by the same in-
terviewer to avoid any discrepancy after ex-
plaining the purpose of information gather-
ing, assurance of personal privacy and con-
sent of the responder.  
 
Inclusion criteria 
Following primary screening, patients 
presented with any one of the below men-
tioned conditions, were suspected for the 
presence of ischemic renal changes. These 
include patients with at least 5-year diabetes 
mellitus and/or 10-year hypertension, cardio-
vascular disease, hypercholesterolemia, 
dyslipidemia, hypoalpha and/or on lipid low-
ering therapy using statins. 
 
Exclusion criteria 
The exclusion criteria encompassed age 
less than 18 year or more than 70 year, pre-
vious revascularization, kidney transplanta-
tion, chronic kidney failure patients on dialy-
sis, liver cirrhosis, hepatitis, AIDS, simulta-
neous presence of chronic inflammatory dis-
eases, current use of steroidal medication, 
failure to complete 4-week statins washout 
period and HDL-C > 30 mg %. 
 
Diagnosis 
Doppler sonography was performed as 
diagnostic tool. Diagnosis was confirmed 
through renal artery Doppler scan performed 
by skilled technician. The scan result was 
considered positive if there was turbulence 
before and after stenosis, maximum flow ve-
locity > 180 cm/sec at stenosis, end-diastolic 
velocity > 50cm/sec, post-stenotic drop in 
velocity, acceleration time > 0.07 seconds 
and slope of systolic upstroke < 3 m/s2 or 
resistance index associated with stenosis or 
occlusion of the segmental arteries < 0.5 (Ng 
et al., 2010). Though, existence or absence 
of ischemic tissue damage was sole decision 
of associated nephrology consultant based on 
clinical picture and Doppler result. 
 
Treatment design 
On the basis of clinical picture and Dop-
pler scan report, finally 135 patients were 
recognized as potential experimental units 
and were requested for consent to participate 
in a follow up study after explaining the pur-
pose and satisfying their queries. Fifteen of 
total identified individuals did not show con-
sent so skipped. While left over were ran-
domly (randomization by computer generat-
ed random number sequence) distributed in 
two treatment groups. Group 1 was pre-
scribed atorvastatin (20 mg/day) and group 2 
NER (500 mg/day) in combination with 
same dose of atorvastatin (20 mg/day) for 
16-weeks in a 1:1 ratio.  
Information regarding personal and fami-
ly medical history, demographics, current 
medication, socio-economic status, physical 
activity, smoking and other required items 
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were taken on a structured questionnaire at 
day first.  
 
Sample collection and analytical  
procedures 
Blood samples were collected from ante-
cubital vein after 12-hour fasting and either 
plasma or serum was separated according to 
the assay requirement. All processed samples 
were stored in 0.5 ml small cuvettes 
at -80 °C unless used for biochemical esti-
mation. 
Inorganic phosphorus was estimated in 
non-hemolysed serum samples using re-
search grade RANDOX, UK kit. Working 
reagent was composed of 28 ml blank rea-
gent (0.36 mol/l sulphuric acid, 154 mmol/l 
sodium chloride) mixed with 12 ml molyb-
date reagent (3.5 mmol/l ammonium molyb-
date, 0.36 mol/l sulphuric acid, 154 mmol/l 
sodium chloride). Standard solution was 
comprised of 5 mg/dl potassium phosphate. 
Working reagent was allowed to react with 
standard and samples for 10 minutes at 25 °C 
in separate test tubes then absorbance was 
measured against reagent blank at 340 nm. 
Inorganic phosphorus concentration was cal-
culated using unitary method of known con-
centration (standard) to unknown (sample). 
Sodium and potassium were measured in 
serum samples using Ion Selective Electrode 
Beckman Coulter AU clinical Chemistry 
Analyzer intended for quantitative measure-
ment of electrolytes.  
According to manufacturer’s instruc-
tions, hemolysis free lithium heparin serum 
samples were used for estimations within 
48 hours after drawing. Apparatus were cali-
brated prior to sample readings using ISE 
low to high serum standards for sodium 
(130-160 mEq/L), for potassium (10-100 
mEq/L) respectively using the particular 
electrodes for both ions. Sample was pre-
pared by adding 20 μL serum in ISE buffer 
triethanolamine and read directly by insert-
ing the specific electrode. Ions concentration 
was measured in mEq/L. 
 
Ethics 
The study was controlled by the direc-
tions set in Declaration of Helsinki and Good 
Clinical Practice standards prescribed by 
World Medical Association (2002). The plan 
was approved from the institutional Board of 
Advanced Study and Research.  
 
Statistical analysis 
Collected data was tabulated and report-
ed as Mean ± S.D. t-Test was used to com-
pare mean values through statistical software 
SPSS 17® at chosen p-value 0.05. Percent 
protection induced by drug treatments was 
calculated by dividing the difference of pre 
and post treatment with control (baseline 
value) and multiplying the result with 100. 
 
RESULTS 
54 patients taking statin while 51 with 
statin NER combination completed the pro-
tocol successfully for four months and as-
sessed for final changes. The basic character-
istics of CKD patients with ischemic renal 
changes assessed for both drug combinations 
are illustrated in Table 1.  
 
 
Table 1: Basic characteristics of the studied pa-
tient groups with ischemic kidney disease admin-
istered atorvastatin alone or atorvastatin in com-
bination with niacin extended release. 
Characteristics 
Statin 
Group 
(n = 60) 
Niacin + 
Statin 
Group 
(n = 60) 
Age (year) 48.6 ± 9.88 46.7 ± 11.2 
Male 39 (65) 42 (70) 
Female 21 (35) 18 (30) 
Body mass index 25 ± 3.2 24 ± 3.8 
Diabetes mellitus 33 (55) 38 (63.3) 
Hypertension 51 (85) 52 (86.6) 
CVD 12 (20) 14 (23.3) 
Anemia 27 (45) 24 (40) 
Current smoker 18 (30) 16 (26.6) 
Ex-smoker 6 (10) 8 (13.3) 
Alcohol 1 (1.6) 1 (1.6) 
Oral tobacco 36 (60) 34 (56.6) 
Values are shown as ‘n ( %)’. The ± values are ‘Mean 
± S.D.’ 
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The effects of NER on lipid profile and 
endothelial function have been discussed by 
same authors earlier (Yasmeen et al., 2014b, 
2015) and not shown here. There was 
marked hyperphosphatemia (p<0.001) and 
hypercalcemia (p<0.01) in disease control 
group as compared with healthy controls, the 
administration of atorvastatin alone for four 
weeks showed a significant decrease in po-
tassium (p<0.05), insignificant decrease in 
phosphorus, whereas, NER significantly re-
duced potassium (p<0.01), phosphorus 
(p<0.001) while variations in serum sodium 
levels remained non-significant among the 
groups (Table 2). 
On comparison of the reduction in potas-
sium and phosphate from respective baseline 
to four months follow up in the patients 
treatment groups either on statin alone or in 
combination with NER, it was found that 
both treatment protocols brought a decrease 
in potassium (p<0.05, p<0.01) respectively 
while in case of phosphorus a generalized 
decrease from baseline value was observed 
though only significant in statin + NER 
group (p<0.001) (Table 3). Thus only NER 
administration not statin alone produced hy-
pophosphatemic effects in patients with 
compromised renal function.  
The mean percent change from baseline 
to follow up further endorsed the finding as 
statin alone brought -47 % reduction in po-
tassium as compared with NER -56 % in 
case of phosphorus it was observed with 
more difference recorded as -14 %, -47 % 
respectively (Figure 1).  
 
 
Table 2: Comparison between electrolytes and inorganic phosphorus in healthy control, disease con-
trol (baseline average values of patients), patients groups of ischemic kidney disease administered 
atorvastatin alone and atorvastatin in combination with niacin extended release for four months. 
 
PARAMETER GROUPS 
Healthy Control 
(n=50) 
Disease Control 
(n=107)1 
Statin  
(n=56)1, 2 
Statin+NER  
(n=51) 1, 2, 3 
Na (mEq/L) 136 ± 4.2 140 ± 4.2NS 145 ± 3.5NS,NS 138 ± 8.6NS,NS,NS 
K (mEq/L) 3.4 ± 0.6 7.8 ± 0.92** 4.15 ± 0.8NS,* 3.72 ± 0.4NS,**,* 
Phosphorus (mg %) 3.2 ± 0.5 6.8 ± 0.4*** 5.6 ± 0.6**,NS 3.6 ± 0.7NS,***,* 
All values are Mean ± S.D. 
NS: Non-significant, *p<0.05, ** p<0.01, ***p<0.001 
1: As compared with healthy control; 2: As compared with disease control; 3: As compared with statin alone 
 
 
Table 3: Effect of atorvastatin alone and atorvastatin in combination with niacin extended release on 
electrolytes and inorganic phosphorus following consumption of four months in patients with ischemic 
kidney disease 
 
PARAMETER Statin Alone 
(n=56) 
Statin + Niacin  
(n=51) 
Na (mEq/L) Baseline 143 ± 5.1 139 ± 3.8 
Follow up 145 ± 3.5NS 138 ± 8.6NS 
K (mEq/L) Baseline 7.8 ± 1.1 8.6 ± 0.8 
Follow up 4.15 ± 0.8* 3.72 ± 0.4** 
Phosphorus (mg/dl) Baseline 6.5 ± 0.4 6.8 ± 0.6 
Follow up 5.6 ± 0.6NS 3.6 ± 0.7*** 
All values are Mean ± S.D. 
NS: Non-significant, *p<0.05, ** p<0.01, ***p<0.001 
Significant difference by student’s t-test from baseline to follow up level
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Figure 1: Mean percent protection induced by 
atorvastatin alone and atorvastatin in combina-
tion with niacin extended release in terms of po-
tassium and inorganic phosphorus levels in pa-
tients with renovascular disease. Negative sign 
indicates reduction in baseline value. 
 
 
DISCUSSION 
Derangments in calcium-phosphorus 
homeostasis particularly markedly raised se-
rum phosphorus levels are considered to play 
a significant role in arterial stiffening, hyper-
tension, and CKD associated CVD risk (Co-
ladonato, 2005; Block et al., 2005).  
Recent published reports about the phos-
phorus-reducing effect of niacin compounds 
in ESRD, specially NER administered once 
per day, confirmed that niacin possesses the 
potential to lessen serum phosphorus that is 
similar in magnitude as attained by admin-
istration of phosphate binders agents taken 
three times in a day and timed requisitely to 
meals (Behets et al., 2004; KDIGO, 2009) 
while NER produced even better outcomes 
on single dose per day as we observed at low 
concentration of 500 mg (Table 2). 
On the other hand we did not find such 
phosphate lowering effect when atorvastatin 
alone administered though it brought a re-
duction in serum phosphate when compared 
to healthy and disease control group but that 
was statistically non-significant (Table 2). 
Similarly when levels compared with follow 
up value with in the group, it caused 12 % 
decrease from baseline that was again non-
significant (Table 3). To the best of our 
knowledge, there is no published data that 
reported significant statin phosphate lower-
ing potential in compromised renal failure or 
in the treatment of dyslipidemia, different 
studies showed that its effect on phosphate is 
non-significant as we noticed (Amara et al., 
2011; Perez-Castrillon et al., 2008) so focus 
of discussion would be NER only.  
The major problem with NER is flushing 
and intolerance that can be overcome by ad-
ministrating the low dose initially and then 
buffered to high dose if required. We found 
the phosphorus lowering effect of NER at 
lower dose of 500 mg/day with a four month 
follow up and had significant decrease 
(p<0.001) in phosphorus level as compared 
to the baseline values (Table 3) while Muller 
et al. (2007) used extended-release niacin 
with comparatively higher dose of 1000 
mg/day in 20 patients for three months with 
similar dropout percentage as we had (15 %) 
because of side effects but this can be in-
creased at high dose with large sample size. 
The long term use (4 vs 3 months) showed 
more percent reduction from baseline, i.e. 
47 % (Table 3) while Muller et al. (2007) 
reported 18 % (P<0.015) they demonstrated 
no significant change in serum calcium or 
iPTH levels. 
Cheng and Young (2008) used niacina-
mide in a randomized, double-blind, place-
bo-controlled crossover trial with 33 indi-
viduals on hemodialysis in dose ranging 
from 500-1500 mg/day and reported signifi-
cant hypophosphatemic effect (P=0.02) in 
agreement of our results (Table 3) while no 
such change was observed with atorvastatin 
alone (Table 3). Maccubbin et al. (2008) did 
a post hoc data analysis of phosphorus levels 
from 1547 patients having dyslipidemia and 
were randomly prescribed with extended re-
lease niacin combined with the selective 
prostaglandin D2 receptor subtype 1 inhibi-
tor laropiprant (NER-L) (n=761), NER alone 
(n=518), or placebo (n=268). They demon-
strated that NER-L and NER alone caused a 
sustained approximately 11 % reduction in 
serum phosphorus [–0.41 mg/dl (–0.46 to –
0.37 mg/dl)]. The common point in all stud-
ies is that there was no significant change in 
serum calcium and NER showed hypophos-
phatemic effect at higher dose (at least 
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1000 mg/day) in contrast to that we adminis-
tered (500 mg/day). A study done by Hyo 
and colleagues (2013) supports our findings 
who reported the similar effects at same low 
dose of NER 500 mg/day in 31 dyslipidemic 
CKD patients with better tolerability.  
Animal model data highlight plausible 
mechanisms, especially fecal loss (Kuboya-
ma et al., 1999) responsible for phosphorus-
reducing impact of niacin formulations. 
Around 50 % of total phosphorus absorbed 
in the duodenum and jejunum by an active 
transport pathway through the epithelial Na-
Pi co-transporters contained in abundantly 
expressed, “ready to use” vesicles located 
within the small intestinal brush border 
(Sampathkumar, 2009). The energy required 
for this active phosphorus transport is pro-
vided by basolateral Na-K-ATPase, Eto and 
fellows (2005) validated in a rat model that 
nicotinamide impedes small intestinal Na-
Pi2b expression, decreasing phosphorus as-
similation and precluding the gradual eleva-
tion in serum phosphorus, a feature of kidney 
failure. Experimental data from healthy rats 
demonstrated that nicotine amide prevents 
sodium-dependent phosphorus co-transport 
in intestine, niacinamide, metabolite of nia-
cin, prevents phosphate absorption in brush 
border membrane vesicles separated from rat 
small intestine (Katai et al., 1999). The pre-
sent study strength is comparatively large 
sample size (n= 
60) with clinically established chronic 
kidney disease of hyperlipidemic renal is-
chemia and longtime of administration (four 
months). While the study limitations are diet 
induced changes in phosphorus concentra-
tion and not assessed effect on serum calci-
um. 
 
CONCLUSION 
The use of NER even at low doses in re-
nal compromised dyslipidemic patients may 
be a promising approach to prevent the 
harmful vascular, valvular effects caused by 
hyperphosphatemia in addition to its princi-
pal target of HDL-C elevation.  
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